Nöroprotektif İlaçlar
Özet
Bu makale, kalp durması, vasküler olaylar veya kafa travması gibi nedenlerle gelişen hipoksik iskemik beyin hasarı ve buna bağlı bilinç bozukluklarının (koma, bitkisel durum ve minimal bilinçlilik) tedavisinde kullanılan nöroprotektif ilaçları ele almaktadır. Bilincin geri kazanılması sürecinde kullanılan farmakolojik ajanlar; santral sinir sistemi (SSS) depresanları ve SSS stimülanları olmak üzere iki ana kategoride gruplandırılmaktadır. SSS depresanlarından zolpidem uyanıklığı geçici olarak artırırken, baklofen spastisiteyi azaltıp omurga-korteks iletimini düzenleyerek, lamotrijin ise özellikle bilişsel performansı destekleyerek fonksiyonel iyileşmeyi teşvik edebilir. SSS stimülanları arasında yer alan dopaminerjik ajanlardan levodopa, amantadin, bromokriptin, apomorfin ve pramipeksol; hasar gören dopaminerjik yolakları uyararak uyanıklık, motor kontrol ve kognitif fonksiyonlarda düzelmeyi hızlandırır. Özellikle amantadin, travmatik beyin hasarı sonrası fonksiyonel iyileşmeyi hızlandırmada en çok çalışılan ve güvenle kullanılan ajandır. Diğer stimülanlardan metilfenidat ve amfetamin dikkat ile öğrenme hızını artırırken, antidepresanlar (SSRI ve trisiklikler) ile modafinil bilişsel, nöropsikiyatrik eksiklikleri ve gündüz uykululuğunu iyileştirir. Sonuç olarak, bilinç bozukluklarının tedavisinde henüz optimal bir tedavi kılavuzu oluşturacak yeterli kanıt bulunmamakla birlikte, her vakanın kendi içinde bütüncül ele alınması ve birleşik yaklaşımlara odaklanan klinik araştırmaların yapılması önerilmektedir.
This article discusses neuroprotective drugs used in the treatment of hypoxic-ischemic brain injury resulting from causes such as cardiac arrest, vascular events, or head trauma, and the associated disorders of consciousness (coma, vegetative state, and minimally conscious state). The pharmacological agents used in the recovery of consciousness are grouped into two main categories: central nervous system (CNS) depressants and CNS stimulants. Among the CNS depressants, zolpidem temporarily increases arousal, baclofen provides improvement by reducing spasticity and regulating spinal-to-cortical transmission, and lamotrigine promotes functional recovery by specifically supporting cognitive performance. Among the CNS stimulants, dopaminergic agents such as levodopa, amantadine, bromocriptine, apomorphine, and pramipexole accelerate recovery in arousal, motor control, and cognitive functions by stimulating damaged dopaminergic pathways. In particular, amantadine is the most studied and safely used agent to accelerate functional recovery after traumatic brain injury. Other stimulants like methylphenidate and amphetamine enhance attention and learning speed, while antidepressants (SSRIs and tricyclics) and modafinil improve cognitive and neuropsychiatric deficits as well as daytime sleepiness. Consequently, although there is not yet sufficient evidence to propose an optimal treatment guideline for disorders of consciousness, it is recommended to manage each case holistically within itself and to conduct clinical research focused on combined approaches.
Referanslar
Plum, F. and J.B. Posner, The diagnosis of stupor and coma. Oxford University Press, USA. Vol. 19. 1982
Working Party of the Royal College of Physicians. The vegetative state: guidance on diagnosis and management. Clin Med (Lond). 2003, 3(3):249-54. doi: 10.7861/clinmedicine.3-3-249.
Giacino JT, Ashwal S, Childs N, et al., The minimally conscious state: definition and diagnostic criteria. Neurology. 2002, 12;58(3):349-53. doi: 10.1212/wnl.58.3.349.
Liepert J. Pharmacotherapy in restorative neurology. Curr Opin Neurol. 2008, 21(6):639-43. doi: 10.1097/WCO.0b013e32831897a3
DeMarchi R, Bansal V, Hung A, et al., Review of awakening agents. Can J Neurol Sci. 2005, 32(1):4-17. doi: 10.1017/s0317167100016826
Pistoia F, Mura E, Govoni S, et al., Awakenings and awareness recovery in disorders of consciousness: is there a role for drugs? CNS Drugs. 2010, 24(8):625-38. doi: 10.2165/11535940-000000000-00000.
Clauss R, Nel W. Drug induced arousal from the permanent vegetative state. NeuroRehabilitation. 2006;21(1):23-8.
Singh R, McDonald C, Dawson K, et al., Zolpidem in a minimally conscious state. Brain Inj. 2008, 22(1):103-6. doi: 10.1080/02699050701829704.
Lo YL, Tan EK, Ratnagopal P, et al., Zolpidem and its effects on hypoxic encephalopathy. Ann Neurol. 2008, 64(4):477-8. doi: 10.1002/ana.21183.
Sarà M, Pistoia F, Mura E, et al., Intrathecal baclofen in patients with persistent vegetative state: 2 hypotheses. Arch Phys Med Rehabil. 2009, 90(7):1245-9. doi: 10.1016/j.apmr.2009.01.012.
Taira T, Hori T. Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. Acta Neurochir Suppl. 2007;97(Pt 1):227-9. doi: 10.1007/978-3-211-33079-1_31
Calabresi P, Centonze D, Cupini LM, et al., Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? Insights from in vitro studies. Neurobiol Dis. 2003, 12(1):82-8. doi: 10.1016/s0969-9961(02)00016-5.
Showalter PE, Kimmel DN. Stimulating consciousness and cognition following severe brain injury: a new potential clinical use for lamotrigine. Brain Inj. 2000, 14(11):997-1001. doi: 10.1080/02699050050191931.
Ockey RR, Mowry D, Varghese G. Use of Sinemet in locked-in syndrome: a report of two cases. Arch Phys Med Rehabil. 1995, 76(9):868-70. doi: 10.1016/s0003-9993(95)80554-0.
Karli DC, Burke DT, Kim HJ, et al., Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation. Brain Inj. 1999, 13(1):63-8. doi: 10.1080/026990599121908.
Saniova B, Drobny M, Kneslova L,et al., The outcome of patients with severe head injuries treated with amantadine sulphate. J Neural Transm (Vienna). 2004, 111(4):511-4. doi: 10.1007/s00702-004-0112-4.
Rogóz Z, Skuza G, Legutko B. Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats. Pharmacol Rep. 2008, 60(6):817-26.
Giacino JT, Whyte J, Bagiella E, et al., Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012, 1;366(9):819-26. doi: 10.1056/NEJMoa1102609.
Sawyer E, Mauro LS, Ohlinger MJ. Amantadine enhancement of arousal and cognition after traumatic brain injury. Ann Pharmacother. 2008, 42(2):247-52. doi: 10.1345/aph.1K284.
Krivonos OV, Amosova NA, Smolentseva IG. Use of the glutamate NMDA receptor antagonist PK-Merz in acute stroke. Neurosci Behav Physiol. 2010, 40(5):529-32. doi: 10.1007/s11055-010-9292-6.
Wu TS, Garmel GM. Improved neurological function after Amantadine treatment in two patients with brain injury. J Emerg Med. 2005, 28(3):289-292. doi: 10.1016/j.jemermed.2004.11.016.
DeMarchi R, Bansal V, Hung A, et al., Review of awakening agents. Can J Neurol Sci. 2005, 32(1):4-17. doi: 10.1017/s0317167100016826.
Fridman EA, Krimchansky BZ, Bonetto M,et al., Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury. Brain Inj. 2010;24(4):636-41. doi: 10.3109/02699051003610433.
Fridman EA, Calvar J, Bonetto M, et al., Fast awakening from minimally conscious state with apomorphine. Brain Inj. 2009, 23(2):172-7. doi: 10.1080/02699050802649662.
Patrick PD, Buck ML, Conaway MR, et al., The use of dopamine enhancing medications with children in low response states following brain injury. Brain Inj. 2003, 17(6):497-506. doi: 10.1080/0269905031000070279.
Whyte J, Hart T, Vaccaro M, et al., Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Phys Med Rehabil. 2004, 83(6):401-20. doi: 10.1097/01.phm.0000128789.75375.d3.
Walker-Batson D, Smith P, Curtis S, et al., Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke. 1995, 26(12):2254-9. doi: 10.1161/01.str.26.12.2254.
Kraus MF. Neuropsychiatric sequelae of stroke and traumatic brain injury: the role of psychostimulants. Int J Psychiatry Med. 1995;25(1):39-51. doi: 10.2190/BXRM-3M58-WBC5-A7EL.
Fann JR, Uomoto JM, Katon WJ. Cognitive improvement with treatment of depression following mild traumatic brain injury. Psychosomatics. 2001, 42(1):48-54. doi: 10.1176/appi.psy.42.1.48.
Stengler-Wenzke K, Müller U. Fluoxetine for OCD after brain injury. Am J Psychiatry. 2002, 159(5):872. doi: 10.1176/appi.ajp.159.5.872.
Perino C, Rago R, Cicolini A, et al., Mood and behavioural disorders following traumatic brain injury: clinical evaluation and pharmacological management. Brain Inj. 2001, 15(2):139-48. doi: 10.1080/026990501458371.
Müller U, Murai T, Bauer-Wittmund T, et al., Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj. 1999, 13(10):805-11. doi: 10.1080/026990599121197.
Saletu B, Saletu M, Grünberger J, et al., Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. Neuropsychobiology. 1993;27(1):26-39. doi: 10.1159/000118950.
Teitelman E. Off-label uses of modafinil. Am J Psychiatry. 2001, 158(8):1341. doi: 10.1176/ajp.158.8.1341.
